Overview
Naturalantibody is a company that streamlines antibody discovery using a comprehensive database that integrates antibody data and employs machine learning solutions for predicting developability issues. It offers tools for structural modeling, paratope prediction, and antibody-antigen docking analysis, along with support for library construction and data visualization. Additionally, it provides free cloud and on-premises versions of its platform for users to manage and analyze their antibody-related data.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2020-12-10. Active
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| May 25, 2023 | Shareholders' meeting convened | |
| Sep 8, 2022 | Shareholders' meeting convened |
Public aid
18 public aid cases recorded, with a total value of $5,544,696.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 29, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | —— | Krakowski Park Technologiczny sp. z o.o. | |
| May 25, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | —— | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Dec 19, 2025 | Aid for SME participation in trade fairs | —— | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
4 projects co-financed from European Funds recorded, with total EU co-financing of $5,530,711.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-01-01 | Wzmocnienie potencjału eksportowego NATURALANTIBODY SPÓŁKA AKCYJNA poprzez udział w wydarzeniach międzynarodowych. | $405.9K$405,873 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2024-11-01 | Opracowanie technologii ekstrakcji danych z literatury naukowej przez duże modele językowe w celu odkrywania przeciwciał terapeutycznych | $853.7K$853,708 | Fundusze Europejskie dla Pomorza Zachodniego 2021-2027 | |
| 2024-04-01 | Opracowanie technologii Specitope służącej do bioinformatycznego przewidywania epitopów specyficznych dla limfocytów B, pozwalającej na identyfikację "in silico" kandydatów na przeciwciała terapeutyczne | $2.4M$2,431,856 | Fundusze Europejskie dla Małopolski 2021-2027 |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
The company shall be represented as follows: a) in the case of a one-person management board, the company shall be represented by the sole member of the management board; b) in the case of a multi-member management board, the company shall be represented by each member of the management board independently; c) in the case of a multi-member management board and the appointment of a Vice-President of the Management Board for financial matters, the company shall be represented by two members of the management board acting jointly, provided that in every case the joint action of the Vice-President of the Management Board for financial matters shall be required.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Konrad Stanisław Krawczyk (40)  | Shareholder of a joint-stock company, 25.79% | |
Wojciech Pysiewicz (49) | Posiadanie 50% udziałów w spółce z o.o. (wp2 investments spółka z ograniczoną odpowiedzialnością) będącej właścicielem 29,29% akcji zgłaszanej spółki akcyjnej (naturalantibody spółka akcyjna) | |
Wojciech Mateusz Pysiewicz (35) | Posiadanie 50% udziałów w spółce z o.o. (wp2 investments spółka z ograniczoną odpowiedzialnością) będącej właścicielem 29,29% akcji zgłaszanej spółki akcyjnej (naturalantibody spółka akcyjna) |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Addeptosp. z o.o. | $5,333,694.00 | addepto.com | ||
| MarcelS.A. | $5,327,708.62 | marcel.pl | ||
| Radpointsp. z o.o. | $4,651,079.57 | radpoint.pl | ||
| ProactaS.A. | $3,747,821.54 | proacta.pl | ||
| FintechS.A. | $3,516,308.88 | fintechsa.pl | ||
| Mineral MidrangeS.A. | $3,356,428.52 | mineralmidrange.com | ||
| Dac.Nextsp. z o.o. | $2,715,267.87 | dac.digital | ||
| Promar Itsp. z o.o. | $2,370,332.83 | promarit.pl | ||
| Innerwebsp. z o.o. | $1,891,798.52 | innerweb.pl | ||
| Data4cure Polandsp. z o.o. | $1,824,382.17 | data4cure.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-01-15 | Address change (Al. Piastów 22, 71-064, Szczecin → Ul. Niemierzyńska 17a/Bud.f1/110, 71-441, Szczecin) | |
| 2025-01-15 | Share capital change (132,979.00 PLN → 136,613.00 PLN) | |
| 2024-08-07 | Share capital change (126,591.00 PLN → 132,979.00 PLN) | |
| 2023-11-24 | Share capital change (108,696.00 PLN → 126,591.00 PLN) | |
| 2021-10-07 | Share capital change (100,000.00 PLN → 108,696.00 PLN) |
FAQ
Last updated: 2026-09-03